UroGen Pharma

UroGen Pharma

Biotechnology Research

Princeton, New Jersey 10,792 followers

About us

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Princeton, New Jersey
Type
Public Company
Founded
2004

Locations

  • Primary

    400 Alexander Park Drive

    4th Floor

    Princeton, New Jersey 08540, US

    Get directions
  • 9 Ha’Ta’asiya Street

    PO Box 2397

    Ra’anana, Central 4365007, IL

    Get directions

Employees at UroGen Pharma

Updates

Similar pages

Browse jobs

Funding

UroGen Pharma 7 total rounds

Last Round

Post IPO equity

US$ 107.5M

See more info on crunchbase